WuXi AppTec - 2025 Company Profile, Funding & Competitors

Q: Where is WuXi AppTec located?

WuXi AppTec is located in Shanghai, China .

Company Details

WuXi AppTec is a provider of a suite of CRO and CDMO services for small molecules, biologics, and medical devices. It offers a suite of services for the research, development, and manufacturing of both small molecules and biologics and also caters to medical device development and has operations all over the globe. They provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody, and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. In 2022, the company recorded annual revenues of $5.84B and a net profit of $1.31B.

Website
Social

Key Metrics

Founded Year

2000

Location

Shanghai, China

Stage

Public

Total Funding

in 5 rounds

Latest Funding Round

Investors

Vivo Capital & 28 more

Ranked

1^st among 834 active competitors

Annual Revenue

as on Dec 31, 2023

Employee Count

as on Dec 31, 2022

Investment & Acquisitions

D3 Bio &

Similar Companies

Eurofins Scientific &

Exit Details

Public

Legal entities associated with WuXi AppTec

WuXi AppTec is associated with 2 legal entities given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
WUXI APPTEC UK LTD	Jan 16, 2011	$8.27M (as on Dec 31, 2023)	290	694
	Dec 31, 1999	-	352	857

Get your free copy of WuXi AppTec's company profile

WuXi AppTec has raised a total funding of $40M over 5 rounds. Its first funding round was on Feb 2007. Its latest funding round was a Post IPO round on Apr 02, 2021 for $15.9M. 1 investor participated in its latest round, which include Vivo Capital, Warburg Pincus, General Atlantic and Temasek.

WuXi AppTec has 29 institutional investors including , Warburg Pincus and General Atlantic.

Here is the list of recent funding rounds of WuXi AppTec:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Apr 02, 2021	$15.9M	Post IPO	6284783	9208737	120 Capital Management
Aug 24, 2020	$951M	Post IPO	4392853	9838570	-
Mar 02, 2016	$1.5B	Conventional Debt	8519935	7566044	Ping An Bank

Access funding benchmarks and valuations. Sign up today!

View details of WuXi AppTec's funding rounds and investors

WuXi AppTec's employee count trend

WuXi AppTec has 1,681 employees as of Dec 22. The total employee count is the same as what it was in Dec 21. Here is WuXi AppTec's employee count trend over the years:

Uncover WuXi AppTec's growth story! Sign up today!

Top competitors of WuXi AppTec include Eurofins Scientific, Ipsen and Avania. Here is the list of Top 10 competitors of WuXi AppTec, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Vivo Capital, Warburg Pincus听&补尘辫;听	63/100
2nd	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	Caisse de depot et placement du Quebec, Holland Capital听&补尘辫;听	68/100
3rd	Ipsen 1929, Boulogne billancourt (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	PAI Partners, 听&补尘辫;听	64/100
4th	Avania 1988, Brunswick (Australia), Acquired	Provider of regulatory, clinical trials and analytic services	-	Omnes Capital, Crescent Capital Group听&补尘辫;听	63/100
5th	ANI Pharmaceuticals 1996, Baudette (United States), Public	Pharmaceutical company developing, manufacturing, and marketing high quality branded and generic prescription drugs	-	First Analysis, JPMorgan Chase听&补尘辫;听	62/100
6th	Red Nucleus 2014, Yardley (United States), Acquired	Provider of advisory, scientific and medical communications for pharmaceutical industry	-	Maranon Capital, Renovus Capital Partners	61/100
7th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	59/100
8th	CHEPLAPHARM 1998, Mesekenhagen (Germany), Late Stage	Pharmaceutical company that specializes in the development, marketing, and distribution of branded pharmaceutical products	$547M	Deutsche Bank, GIC听&补尘辫;听	58/100
9th	China Medical System 1992, Shenzhen (China), Public	Manufacturer of generic formulations	-	CMS Ventures	57/100
10th	NightHawk Biosciences 2008, Morrisville (United States), Public	Fully integrated biopharmaceutical company	-	Seed-One Ventures	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on WuXi AppTec's competitors? Click to see the top ones

WuXi AppTec has made 39 investments in companies including D3 Bio and Structure. WuXi AppTec has also acquired 10 companies including OXGENE and Mingjie Pharmaceutical. Here is the list of investments & acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 08, 2024	Investments	D3 Bio	2018	Shanghai, China
Oct 20, 2021	Investments	Structure	2017	San Francisco, United States
Jun 03, 2021	Investments	Siwei Biotechnology	2016	Pudong, China